tradingkey.logo

Penumbra Inc

PEN
View Detailed Chart

292.605USD

-4.305-1.45%
Close 04/30, 16:00ETQuotes delayed by 15 min
11.32BMarket Cap
807.81P/E TTM

Penumbra Inc

292.605

-4.305-1.45%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.45%

5 Days

+4.96%

1 Month

-3.47%

6 Months

+27.85%

Year to Date

+23.21%

1 Year

+48.93%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 20 analysts
BUY
Current Rating
318.882
Target Price
7.40%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

111
Total
7
Median
9
Average
Company name
Ratings
Analysts
Penumbra Inc
PEN
20
Medtronic PLC
MDT
34
Stryker Corp
SYK
33
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
28
Dexcom Inc
DXCM
26
1
2
3
...
22

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(3)
Neutral(2)
Buy(7)
Indicators
Sell(2)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
5.047
Buy
RSI(14)
62.636
Neutral
STOCH(KDJ)(9,3,3)
78.849
Neutral
ATR(14)
12.063
Low Volatility
CCI(14)
121.580
Buy
Williams %R
16.833
Overbought
TRIX(12,20)
0.277
Sell
StochRSI(14)
77.858
Sell
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
294.206
Sell
MA10
284.629
Buy
MA20
276.811
Buy
MA50
271.136
Buy
MA100
254.244
Buy
MA200
222.091
Buy

News

More news coming soon, stay tuned...

Company

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Company codePEN
CompanyPenumbra Inc
CEOMr. Adam Elsesser, J.D.
Websitehttps://www.penumbrainc.com/